Abstract:5048 Background: We previously reported that circulating serum biomarkers of bone metabolism were significantly associated with overall survival (OS) in men with advanced prostate cancer, either in the hormone sensitive (Lara, et al. ASCO 2022) or castration resistant state (Lara, et al. JNCI 2016). In S1216, we showed that elevated bone biomarkers were significantly associated with an increased risk of death in HSPC regardless of bone metastases (mets). We also identified three risk groups (low, intermediate, and poor) with differential OS outcomes (median OS: 8.2, 5.1, and 2.1 years, respectively) based on combinations of bone biomarkers in these patients. Here we report the association of bone biomarkers with OS in men with HSPC and documented skeletal mets as part of a planned analysis of S1216. Methods: Bone resorption [C-telopeptide (CTx) and Pyridinoline (PYD)] and bone formation markers [C-terminal collagen propeptide (CICP) and bone alkaline phosphatase (BAP)] were assessed from patient sera. Patients were randomly divided into training (n=238) and validation (n=475) sets. In the training set, recursive partitioning that maximizes discrimination of OS was used to identify the dichotomous cut-point for each biomarker and for a combination of biomarker split points to define prognostic groups. In the validation set, Cox proportional hazards models were used to assess the impact of biomarkers on OS, adjusted for patient and tumor characteristics. Results: Of 1,279 men in S1216, 713 had both baseline bone mets and evaluable bone biomarkers. Patient characteristics were similar between the overall population and the subset with bone mets. Elevated levels of CICP, CTX, and PYD were strongly prognostic for OS, but not for BAP. Hazard ratios (95% CI) for OS adjusted for treatment arm and baseline clinical variables were: BAP – 1.31 (0.93, 1.84), p=0.12; CICP – 1.58 (1.09, 2.29), p 0.2). Recursive partitioning algorithms identified four groups of patients with differential OS outcomes based on bone biomarkers, adjusted for baseline clinical variables, with median OS ranging from 2.3 years (highest risk group) to 7.5 years (lowest risk group). Conclusions: In this subset analysis of men with HSPC and bone mets in S1216, elevated serum markers of bone metabolism were significantly associated with worse OS. Bone biomarker levels alone and in combination with patient and tumor characteristics identify unique subsets of men with differential OS outcomes. Clinical trial information: NCT01809691 .

Predictive Significance of Bone Sialoprotein and Osteopontin for Bone Metastases in Respectable Non-Small Cell Lung Cancer: A Retrospective Study

Osteopontin Is A Useful Predictor Of Bone Metastasis And Survival In Patients With Locally Advanced Nasopharyngeal Carcinoma

Sites of Synchronous Distant Metastases and Prognosis in Prostate Cancer Patients with Bone Metastases at Initial Diagnosis: a Population-Based Study of 16,643 Patients.

Prognostic significance of serum osteopontin levels in small cell lung cancer

Bone sialoprotein promotes lung cancer osteolytic bone metastasis via MMP14-dependent mechanisms

Differential Expression of the RANKL/RANK/OPG System is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer

Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Clinical Features and Prognostic Factors in Patients with Bone Metastases from Non-Small Cell Lung Cancer

The Prognostic Value of Osteopontin in Limited-Stage Small Cell Lung Cancer Patients and Its Mechanism.

Clinical and in Vitro Analysis of Osteopontin As a Prognostic Indicator and Unveil Its Potential Downstream Targets in Bladder Cancer

OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and Its Effects on the Bone Metastatic Abilities of Lung Cancer Cells in Vitro.

Predictive and Prognostic Value of Serum Periostin in Advanced Non–small Cell Lung Cancer Patients Receiving Chemotherapy

SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation

Bone Turnover Markers As Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Serum BMP-2 Up-regulation As an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

BMPR2 and HIF1-α Overexpression in Resected Osteosarcoma Correlates with Distant Metastasis and Patient Survival

The Impact of Osteopontin on Prognosis and Clinicopathology of Colorectal Cancer Patients: a Systematic Meta-Analysis

Osteopontin As a Multifaceted Driver of Bone Metastasis and Drug Resistance

Metabolic phenotypes, serum tumor markers, and histopathological subtypes in predicting bone metastasis: analysis of 695 patients with lung cancer in China